Results for tag: "Cabometyx"

Cabometyx is a drug used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer. It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Cabometyx is approved by the US Food and Drug Administration (FDA) for the treatment of advanced RCC in adults. It is also approved for the treatment of hepatocellular carcinoma (HCC) in adults. Cabometyx is used in combination with other drugs to treat advanced RCC. It is also used as a single agent to treat HCC. The drug is available in tablet form and is taken orally. Cabometyx is marketed by Exelixis, Inc. in the United States and by Ipsen Biopharmaceuticals in Europe. Other companies involved in the market include Bristol-Myers Squibb, Merck, Pfizer, and Roche. Show Less Read more